Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. provides comprehensive kidney care through a global dialysis and care-delivery network. Company news commonly covers quarterly operating results, revenue per treatment, patient care costs, reimbursement trends, share repurchases and investor conference participation.
Updates also address DaVita's value-based kidney care programs, coordinated care arrangements, and services that support patients across stages and settings of kidney disease, including home support, outpatient dialysis centers, hospitals, skilled nursing facilities and transplantation-related care.
DaVita Integrated Kidney Care (IKC) has appointed Dr. David Roer as its new chief medical officer, leading a team of experienced nephrologists to enhance care delivery. The team aims to improve patient care for chronic kidney disease and increase access to home dialysis and kidney transplantation. DaVita IKC currently manages over 30,000 patients and anticipates more than doubling its patient population in 2022 due to new Medicare payment models. This initiative aligns with DaVita's goal of advancing health equity in kidney care.
DaVita Inc has achieved a significant milestone by becoming the first kidney care provider to operate entirely on renewable energy for its North American facilities. This initiative, completed in partnership with Longroad Energy, involved constructing a wind farm and a solar farm in Texas. The company now aims for 100% renewable energy globally by 2025 and has already reduced carbon emissions per dialysis treatment by 19%. Other sustainability efforts include installing energy-efficient systems in 1,200 centers and diverting over 6 million pounds of waste from landfills.
DaVita's 15th annual Tour DaVita event successfully raised nearly $1 million for Bridge of Life, a nonprofit dedicated to improving global healthcare. The event, held virtually from October 1–3, saw around 3,400 participants logging over 26,000 miles to raise awareness for kidney disease. Bridge of Life aims to provide healthcare services in underserved areas, especially crucial during the COVID-19 pandemic. Sponsors included AmerisourceBergen and Wells Fargo, underscoring community support for healthcare initiatives.
On November 29, 2021, DaVita Clinical Research published a study highlighting the effectiveness of mRNA COVID-19 vaccines in dialysis patients. The study found that vaccinated patients had a 78% and 73% efficacy against COVID-19 infection from Pfizer/BioNTech and Moderna vaccines, respectively. Vaccinated individuals were also less likely to experience hospitalization or death following breakthrough infections. This research is significant as it addresses a vulnerable group previously underrepresented in vaccine trials, providing reassurance regarding vaccination's protective benefits for over 500,000 Americans with end-stage kidney disease.
DaVita Clinical Research (DCR) will present eight research abstracts at the ASN Kidney Week 2021, taking place from Nov. 4-7. The event will host over 13,000 kidney care professionals discussing advancements in nephrology. DCR's studies will focus on COVID-19 prevention and improving clinical outcomes, including the effectiveness of mRNA vaccines in dialysis patients. Notable abstracts cover predictive algorithms for hospitalizations and safety of treatments in dialysis centers. DCR aims to enhance collaborative efforts in kidney disease management and clinical research.
In November 2021, DaVita and the American Diabetes Association (ADA) collaborate for American Diabetes Month, focusing on the link between diabetes and kidney disease. The initiative aims to educate and provide resources, having reached 35 million people to date. About 1.5 million Americans are diagnosed with diabetes annually, and 37 million live with kidney disease. The campaign promotes preventive measures and includes live discussions and access to kidney-friendly resources. DaVita serves 241,600 patients across over 3,100 outpatient dialysis centers globally.
DaVita Inc. (NYSE: DVA) reported strong financial results for Q3 2021, achieving diluted earnings per share of $2.36, up 84.4% year-over-year. Consolidated revenues reached $2.938 billion, with operating income at $475 million. Operating cash flow was $567 million and free cash flow was $358 million. The company repurchased 2.731 million shares at an average cost of $123.14. Despite challenges from COVID-19 and a tough labor market, DaVita continues to deliver quality care and execute its strategic plan.
DaVita Inc. (NYSE: DVA) will hold a virtual Capital Markets Day on November 16, 2021, from 10:00 a.m. to 12:00 p.m. Eastern Time. Investors can join the live webcast through a provided link on their investor website. The event will discuss the company’s strategies and performance, emphasizing its commitment to improving quality of life for patients while being one of the largest kidney care providers in the U.S. As of June 30, 2021, DaVita served over 204,300 patients across 2,828 outpatient dialysis centers in the U.S. and operates internationally.
DaVita Inc. (NYSE: DVA) will hold its quarterly conference call on October 28, 2021, at 5:00 p.m. Eastern Time to discuss its third quarter results. The results will be available after market close that day. Interested parties can listen via webcast on the DaVita investor relations website, or by dialing in using the provided numbers. DaVita is a leading kidney care provider that serves over 204,300 patients at 2,828 outpatient dialysis centers in the U.S. and operates an additional 331 centers globally.
Summary not available.